TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11298850
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group with advice to quit smoking and lower fat and glucose consumption, similar antihypertensive treatment as intervention group.
Study: 8100627
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker plus placebo
Study: 29773463
Drug: Alarm system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm system treatment for 16 weeks (Group B)
Study: 29773463
Drug: Alarm system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm system treatment for 20 weeks (Group C)
Study: 29773463
Drug: Alarm system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm system treatment for 12 weeks (Group A)
Study: 27777127
Drug: Electronic Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic Medication Complete Communication (EMC2) Strategy
Study: 19476474
Drug: linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 2.5 mg
Study: 10704632
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg)
Study: 17571283
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg)
Study: 14568892
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg)
Study: 17102570
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg)
Study: 9926538
Drug: Twelve Step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve Step Facilitation Therapy (TSF)
Study: 9926538
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Coping Skills Therapy (CBT)
Study: 7831650
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - enoxaparin 4000 anti-Xa units once a day subcutaneously for 3 months
Study: 7831650
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment for 3 months
Study: 7831650
Drug: Warfarin during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin during 9-month follow-up
Study: 7831650
Drug: Warfarin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin after one year
Study: 2978782
Drug: Routine (ordinary,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine (ordinary, manual) regimens of oral hygiene
Study: 7007588
Drug: High-dose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroid regimen
Study: 7007588
Drug: Low-dose steroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose steroid regimen
Study: 6986243
Drug: Antacids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids alone
Study: 7007588
Drug: Antacids supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids supplemented with cimetidine
Study: 1557840
Drug: Mini-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-dose heparin
Study: 7007588
Drug: Full-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose heparin
Study: 23024440
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 × 8 mg/d (dex-early)
Study: 19123142
Drug: Levofloxacin 0.5%
Normalized name: LEVOFLOXACIN 0.5% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 0.5% eyedrops three times daily for 5 days
Study: 19123142
Drug: Classic dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic dosage group (every 2 hours on days 1 and 2, then every 4 hours on days 3-5)
Study: 17447828
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg/day during week 1, 300 mg/day during week 2, then 200, 300 or 400 mg/day based on efficacy and tolerability assessment.
Study: 2545054
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (1500 aPTT U) combined with 0.5 mg dihydroergotamine (LMH/DHE)
Study: 2545054
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (2500 IU) combined with 0.5 mg dihydroergotamine (H/DHE)
Study: 790113
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate by inhalation (400 mug/day)
Study: 21913053
Drug: Atazanavir (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (300/100 mg once daily)
Study: 14743040
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (5 pairs)
Study: 11502515
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of vancomycin (CIV)
Study: 30391914
Drug: Intermittent infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent infusions of vancomycin (IIV)
Study: 9509950
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of aspirin (ASA)
Study: 7512101
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of terfenadine
Study: 2975583
Drug: Depotmedroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depotmedroxyprogesterone acetate (Depoprovera) 150 mg every 84 +/- 7 days
Study: 2975583
Drug: Norethisterone enanthate
Normalized name: norethindrone enanthate
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone enanthate (Noristerat) 200 mg every 56 +/- 7 days
Study: 29037984
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (administered every 3-4 weeks for six doses, then every 3-6 months until the end of 5 years)
Study: 29037984
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (standard adjuvant systemic therapy alone)
Study: 21247520
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid plus low-dose statin
Study: 21247520
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid plus moderate-dose statin
Study: 21247520
Drug: Low-dose statin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose statin monotherapy
Study: 21247520
Drug: Moderate-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose statin monotherapy
Study: 21247520
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin monotherapy
Study: 21247520
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination treatment
Study: 21247520
Drug: Moderate-dose combination
Normalized name: Corticosteroids, moderately potent, other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose combination treatment
Study: 21247520
Drug: Corresponding-dose statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding-dose statins
Study: 17495988
Drug: Immediate cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cognitive therapy for 12 weeks (mean of 5.9 sessions during 12 weeks and 2.0 sessions thereafter)
Study: 17495988
Drug: Immediate cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cognitive therapy for 12 weeks
Study: 12920367
Drug: Daivobet (calcipotriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivobet (calcipotriol 50 micro g/g, betamethasone dipropionate 0.5 mg/g)
Study: 12920367
Drug: Diproson (betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diproson (betamethasone dipropionate 0.05 mg/g)
Study: 3519092
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acebutolol once daily for 12 weeks
Study: 15822738
Drug: Amithryptiline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amithryptiline (50 mg/day)
Study: 15822738
Drug: Amithryptiline (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amithryptiline (reduced dosage) combined with Dysport
Study: 12032787
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg every 24 hours (once-daily regimen)
Study: 12032787
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg every 12 hours (twice-daily regimen)
Study: 10354195
Drug: Moderate red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate red wine consumption (50 g per day of alcohol)
Study: 8933894
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS) 4 mg administered via inhalation chamber 30 minutes prior to exercise
Study: 8933894
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS) 4 mg every 8 hours during four weeks plus 4 mg of NS 30 minutes before exercise
Study: 8933894
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg prior to exercise)
Study: 6407714
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg vitamin E (DL‐alpha‐tocopherol acetate) intramuscularly after birth (day 0) and on days 1, 2, and 3
Study: 30747897
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy combined with chemotherapy (docetaxel)
Study: 30747897
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy combined with abiraterone
Study: 30477839
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day saffron for 8 weeks
Study: 24619599
Drug: Coordinated Anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated Anxiety Learning and Management (CALM) treatment
Study: 22801094
Drug: AS03-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted vaccine (3.75 µg HA/AS03A or 1.9 µg HA/AS03B)
Study: 22801094
Drug: Nonadjuvanted 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted 15 µg HA vaccine
Study: 22801094
Drug: Nonadjuvanted 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted 7.5 µg HA vaccine
Study: 22801094
Drug: All vaccines
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccines except nonadjuvanted 7.5 µg HA vaccine
Study: 15738746
Drug: Pregabalin 200
Normalized name: pregabalin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 200 mg/d (BID)
Study: 15738746
Drug: Pregabalin 400
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 400 mg/d (BID)
Study: 15738746
Drug: Pregabalin 450
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 450 mg/d (TID)
Study: 11954670
Drug: Therapeutic biking
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic biking using a wheelchair bicycle in a recreation therapy protocol
Study: 393383
Drug: 15 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/week of 5-fluorouracil by oral route
Study: 393383
Drug: 15 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/week of 5-fluorouracil by iv route
Study: 30606886
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment of tamoxifen followed by exemestane for 5 years
Study: 28893875
Drug: zoledronate (1-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: zoledronate (1-5 mg)
Study: 19496762
Drug: +4 degrees
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: +4 degrees C Ringer's solution with a target temperature of 33 degrees C
Study: 16943110
Drug: Insulin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.3 IU/kg)
Study: 23295625
Drug: NaF/SiO2‐based toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF/SiO2‐based toothpaste (1,100 µg F/g as labeled, 1,129.7 ± 49.4 µg F/g soluble fluoride as analyzed)
Study: 23295625
Drug: Na2FPO3/CaCO3‐based toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na2FPO3/CaCO3‐based toothpaste (1,450 µg F/g as labeled, 1,122.4 ± 76.4 µg F/g soluble fluoride as analyzed)
Study: 15020281
Drug: Dexamethasone before
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone before chemotherapy
Study: 11736726
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication therapy (proton pump inhibitor-based)
Study: 10212830
Drug: D‐chiro‐inositol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐chiro‐inositol administered to STZ diabetic rats and rhesus monkeys
Study: 10212830
Drug: D‐chiro‐inositol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐chiro‐inositol administered to humans with impaired glucose tolerance
Study: 10212830
Drug: D‐chiro‐inositol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐chiro‐inositol administered to women with PCOS
Study: 20536477
Drug: Strip patch
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Strip patch test
Study: 28271532
Drug: Conventional patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional patch test
Study: 17348460
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) followed by cisplatin (75 mg/m2)
Study: 17348460
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2 i.v.) and cyclophosphamide (700 mg/m2 i.v.)
Study: 11230751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon (IFN) and ribavirin for either 24 or 48 weeks
Study: 11230751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon (IFN) and ribavirin
Study: 799978
Drug: Maprotiline 25
Normalized name: maprotiline 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 25 mg orally twice daily
Study: 799978
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg orally twice daily
Study: 27753785
Drug: Higher mean
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher mean daily intensity level of 10-minute activity sessions
Study: 25413377
Drug: Linezolid continuous
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid continuous infusion (CI)
Study: 25413377
Drug: Linezolid intermittent
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid intermittent infusion (II)
Study: 21688301
Drug: Etanercept (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50mg subcutaneously weekly)
Study: 19879233
Drug: Tat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat vaccine administered 5 times monthly, subcutaneously in alum or intradermically alone at 7.5 microg, 15 microg or 30 microg
Study: 20028332
Drug: Tat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat vaccine
Study: 17726413
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 10-15 mcg/kg
Study: 17726413
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine sulfate (IV morphine) 0.1 mg/kg
Study: 17726413
Drug: Both OTFC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both OTFC and IV morphine
Study: 9577286
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (eutectic mixture of local anaesthetics)
Study: 7697403
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg per day)
Study: 7697403
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and dietary salt reduction
Study: 31805922
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment (Group A)
Study: 25463415
Drug: Treatment-related SAEs
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related SAEs
Study: 23458225
Drug: Liposome bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome bupivacaine 40 mg
Study: 23458225
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 7.5 mg
Study: 15150840
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of combined AZT/3TC tablets
Study: 2662700
Drug: Methionyl GH
Normalized name: N-Methionylleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Methionyl GH (somatrem), 2 IU per m2 body surface s.c. daily
Study: 30148987
Drug: Conbercept (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept (0.5 mg) administered intravitreally once monthly for the first 3 months, then once quarterly until month 12.
Study: 30148987
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control group received first 3 monthly sham injections followed by 3 monthly injections of conbercept (0.5 mg) until month 12.
Study: 25010554
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1000 mg daily
Study: 22170716
Drug: 17β‐estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐estradiol (2 mg/d) for the first 6 months
Study: 22170716
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/d) for the remaining 18 months
Study: 20128040
Drug: Muscle relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle relaxant medication
Study: 17912222
Drug: Continuous ambulatory
Normalized name: Continuous ambulatory peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ambulatory peritoneal dialysis (CAPD) with conventional dialysis solutions
Study: 17912222
Drug: Icodextrin based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin based solution
Study: 7646090
Drug: Intravenous prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostacyclin
Study: 8677156
Drug: Cytostatic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytostatic agents (VCR + Rub, L‐aspa, CY, Ara‐C)
Study: 31986446
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in a medicine take-back program
Study: 31986446
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to pay for a medicine disposal program
Study: 28916992
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D3 (400 IU)
Study: 28916992
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D3 (1000 IU)
Study: 17493496
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of epinephrine
Study: 15505276
Drug: TAM 30
Normalized name: Pentam 300
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAM 30 mg/d for 3 years
Study: 15505276
Drug: EPI 30
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI 30 mg on days 1, 8, and 15 every 28 days for six cycles plus TAM 30 mg/d for 3 years
Study: 29792232
Drug: CI-guided goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-guided goal-directed hemodynamic therapy (GDHT)
Study: 15735202
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment for 10 days (T(2)D+); plasma glucose 5.5 ± 0.2 mmol/l
Study: 15735202
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of all antidiabetic medications for 2 weeks (T(2)D-); plasma glucose 12.6 ± 1.0 mmol/l
Study: 11895895
Drug: BCL-2 antisense
Normalized name: Exon 53 specific antisense morpholino oligonucleotide
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BCL-2 antisense oligonucleotide (G3139) at 6.9 mg/kg/day
Study: 10332543
Drug: Intravenous salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous salmon calcitonin 200 IU
Study: 9102059
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin
Study: 10332543
Drug: Long-term studies
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term studies using intranasal calcitonin
Study: 7676060
Drug: Parenteral spread
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral spread of infections agents
Study: 2202902
Drug: Isotretinoin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (50 to 100 mg per square meter of body-surface area per day)